Program
MRNA-1195
A development code. Also written as “mRNA-1195”, “mRNA-1195.1” and “mRNA-1195.2”.
Its studies are mostly in Epstein-Barr Virus Infections · Multiple Sclerosis, led by Moderna.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 21 open or running | phase 2since Dec 11, 2024 | Apr 14, 2023 | Jan 8, 2029phase 2 · NCT06735248 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2023First study: phase 1 study in Epstein-Barr Virus InfectionsFirst studyNCT05831111 · 482 enrolled · United States
- Dec 11, 2024Phase 2 study in Multiple SclerosisNCT06735248 · 180 planned · United States, Australia, United Kingdom
Ahead
- Jan 8, 2029Primary completion: phase 2 study in Multiple SclerosisNCT06735248
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06735248Multiple Sclerosis · United States, Australia, United Kingdom | 2 | Recruiting | Jan 8, 2029 | 180 |
| NCT05831111Epstein-Barr Virus Infections · United States | 1 | Completed | Oct 14, 2026 | 482 |
How it is read
Names in the registry
- “mRNA-1195”, 2 entries
- “mRNA-1195.1”, 1 entry
- “mRNA-1195.2”, 1 entry
Codes read as this program: MRNA1195.
Conditions, from the studies’ own filings
- Epstein-Barr Virus Infections, 1 study
- Multiple Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.